Publicacións en colaboración con investigadores/as de Stanford University (8)

2020

  1. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2015

  1. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

    Journal of the American Heart Association, Vol. 5, Núm. 3

2011

  1. Report from a consensus conference on antibody-mediated rejection in heart transplantation

    Journal of Heart and Lung Transplantation, Vol. 30, Núm. 3, pp. 252-269

2010

  1. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients

    Journal of Heart and Lung Transplantation

2006

  1. Foreword: One day update on heart failure

    European Heart Journal, Supplement